These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2349079)

  • 21. Experimental evidence of interleukin-2 activity in bone marrow transplantation.
    Mazumder A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S37-42. PubMed ID: 9457392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant human interleukin-2 restores in vitro T-cell colony formation by peripheral blood mononuclear cells after autologous bone marrow transplantation.
    Bosly AE; Staquet PJ; Doyen CM; Chatelain BJ; Humblet YP; Symann ML
    Exp Hematol; 1987 Nov; 15(10):1048-54. PubMed ID: 3311785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies.
    Fefer A; Benyunes M; Higuchi C; York A; Massumoto C; Lindgren C; Buckner CD; Thompson JA
    Acta Haematol; 1993; 89 Suppl 1():2-7. PubMed ID: 8475668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Constitutive and mitogen-stimulated cytokine mRNA expression by peripheral blood mononuclear cells from most autologous and allogeneic bone marrow transplant recipients is intact.
    Lum LG; Joshi ID; Smith MR; Ratanatharathorn V; Galoforo SC; Karanes C; Uberti JP; Sensenbrenner LL
    Bone Marrow Transplant; 1994 Feb; 13(2):187-95. PubMed ID: 8205088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of two distinct natural killer-cell populations, activated T cells and antineoplastic cytokines, by interleukin-2 therapy in children with solid tumors.
    Dilloo D; Laws HJ; Hanenberg H; Körholz D; Nürnberger W; Burdach SE
    Exp Hematol; 1994 Oct; 22(11):1081-8. PubMed ID: 7925775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy with interleukin 2 after ABMT in AML.
    Hamon MD; Prentice HG; Gottlieb DJ; Macdonald ID; Cunningham JM; Smith OP; Gilmore M; Gandhi L; Collis C
    Bone Marrow Transplant; 1993 May; 11(5):399-401. PubMed ID: 8504274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of minimal residual disease in patients with childhood common acute lymphoblastic leukemia after autologous bone marrow transplantation with ex vivo purging and systemic IL-2 infusion: unsuccessful prediction of subsequent relapse.
    Kiyoi H; Kojima S; Kato K; Matsuyama T; Kodera Y; Ohno R; Naoe T
    Bone Marrow Transplant; 1995 Sep; 16(3):437-42. PubMed ID: 8535317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patients.
    Messina C; Zambello R; Rossetti F; Gazzola MV; Varotto S; Destro R; Basso G; Semenzato G; Zanesco L
    Bone Marrow Transplant; 1996 May; 17(5):729-35. PubMed ID: 8733689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preliminary characterization of functional residual host-type T lymphocytes following conditioning for allogeneic HLA-matched bone marrow transplantation (BMT).
    Kedar E; Or R; Naparstek E; Zeira E; Slavin S
    Bone Marrow Transplant; 1988 Mar; 3(2):129-40. PubMed ID: 3048477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Humoral immunodeficiency in patients after bone marrow transplantation.
    Körholz D; Kunst D; Hempel L; Söhngen D; Heyll A; Mauz-Körholz C; Zintl F; Burdach S
    Bone Marrow Transplant; 1996 Dec; 18(6):1123-30. PubMed ID: 8971382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy with recombinant human interleukin 2 in patients with hematological malignancies after bone marrow or peripheral blood stem cell transplantation.
    Frydecka I; Kosmaczewska A; Boćko D; Ciszak L; Kaczmarek P
    Arch Immunol Ther Exp (Warsz); 1999; 47(4):223-7. PubMed ID: 10483870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-7 drives donor T cell proliferation and can costimulate cytokine secretion after MHC-matched allogeneic bone marrow transplantation.
    Levy RB; Jones M; Hamilton BL; Paupe J; Horowitz T; Riley R
    J Immunol; 1995 Jan; 154(1):106-15. PubMed ID: 7995931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abnormal T-lymphocyte colonies (CFU-TL) following bone marrow transplantation.
    Mitsuyasu RT; Li SN; Champlin RE; Gale RP
    Exp Hematol; 1986 Dec; 14(11):1049-55. PubMed ID: 3536545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex.
    Rowe JM; Rapoport AP; Ryan DH; Nilsson BI; Duerst RE; Packman CH; Abboud CN; DiPersio JF; Linder T; Wang N; Simonsson B; Liesveld JL
    Bone Marrow Transplant; 1999 Nov; 24(10):1057-63. PubMed ID: 10578155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
    Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
    In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripheral blood mononuclear cells from autologous hematopoietic stem cell transplantation recipients produce and respond to IL-12.
    Guillaume T; Kubin M; Sekhavat M; Rubinstein DB; Trinchieri G; Symann M
    Bone Marrow Transplant; 1996 Oct; 18(4):733-9. PubMed ID: 8899188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone marrow stromal cell line co-transfected with IL-2 and IL-3 genes can accelerate restoration of T-cell immunity in allo-BMT mice.
    Li AL; Jiang JY; Ma JB; Wang GM; Hao J; Gao X; Xie SS
    Chin Med J (Engl); 2004 Aug; 117(8):1223-7. PubMed ID: 15361299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study.
    Blaise D; Stoppa AM; Olive D; Brandely M; Tiberghien P; Attal M; Attal J; Reiffers J; Demeocq F; Pico JL
    Bone Marrow Transplant; 1991; 7 Suppl 2():146. PubMed ID: 1878687
    [No Abstract]   [Full Text] [Related]  

  • 39. Human bone marrow allograft recipients: production of, and responsiveness to, interleukin 2.
    Warren HS; Atkinson K; Pembrey RG; Biggs JC
    J Immunol; 1983 Oct; 131(4):1771-5. PubMed ID: 6352802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration.
    Klingemann HG; Eaves CJ; Barnett MJ; Eaves AC; Hogge DE; Nantel SH; Reece E; Shepherd JD; Sutherland HJ; Phillips GL
    Bone Marrow Transplant; 1994 Sep; 14(3):389-96. PubMed ID: 7994260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.